Table 4.
Urinary biomarkers in established AKI without further progression
| Non-AKI (n = 208, 61.4%) | Established AKI without progression (n = 47, 13.8%) | AKI progression (n = 84, 24.8%) | |
|---|---|---|---|
| Semaphorin 3A (ng/gCre) | 441.5 [166.0–844.0] | 586.7 [354.6–1063.6] | 1157.7 [453.4–2185.9]*# |
| L-FABP (μg/gCre) | 14.7 [3.4–72.4] | 79.4 [30.6–723.6]# | 154.6 [23.2–623.7]# |
| NGAL (μg/gCre) | 39.5 [15.1–143.0] | 278.9 [56.4–934.0]# | 151.1 [51.1–665.4]# |
| IL-18 (ng/gCre) | 134.4 [63.8–352.2] | 472.5 [177.1–1088.3]# | 427.2 [181.4–1132.5]# |
| Alb (mg/gCre) | 87.6 [42.1–189.2] | 269.7 [162.5–759.1]# | 290.4 [111.4–629.8]# |
| NAG (IU/gCre) | 19.9 [9.5–41.9] | 35.4 [21.2–49.9]# | 41.9 [21.7–86.5]# |
Values are presented as median [interquartile range].
*P < 0.05 versus established AKI without progression; #P < 0.05 versus non-AKI.